Sorafenib in advanced hepatocellular carcinoma.

By G. Spinzi, S. Paggi. New England Journal of Medicine, 2008

7,076 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/82d7333128b32a7c1740da3179b27abde752f853

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, background): “Sorafenib is an oral multikinase inhibitor that initially demonstrated a survival advantage in the front-line setting in a phase 3 double-blind, placebo-controlled trial(167) (Table 3).”
AASLD guidelines for the treatment of hepatocellular carcinoma (2018, background): “Of the agents evaluated in the adjuvant setting, only sorafenib has been shown to improve survival in advanced disease,((52)) yet it ultimately did not show any improvement in outcomes for the adjuvant treatment of HCC in randomized studies.”
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (2016, background): “We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC.”
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer (2013, neutral): “5 Sex (n (%)) Male 13 (81) 10 (71) Female 3 (19) 4 (29) Region (n (%)) North America 9 (56) 8 (57) Asia 7 (44) 6 (43) Cause of disease (n (%)) Virally associated 9 (56) 9 (64) HCV 3 (19) 3 (21) HBV 6 (37) 6 (43) Alcohol only 0 (0) 2 (14) Other 7 (44) 3 (21) Karnofsky performance status (KPS) of 70–1”
Advances in immunotherapy for hepatocellular carcinoma (2021, neutral): “Nivolumab (1 mg/kg every 3 weeks) Ipilimumab (3 mg/kg every 3 weeks) 2L 50 36 80 50 32 (8) 40 22.”
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, methodology): “8 months compared with 95 placebo (10·7 months vs 7·9 months; hazard ratio [HR] 0·69; p<0·001) despite a low response rate of 96 2%.(4) In patients from the Asia-Pacific region who were taking sorafenib, the median improvement in 97 overall survival over placebo was 2·3 months (6·5 months vs 4·2 mon”
A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization (2009, result): “UNOS/new lesion Progressed 12 (34) 12 (28) 0.”
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (2009, background): “Recent data have established Sorafenib as the preferred systemic therapy for advanced HCC [8].”
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma (2018, neutral): “Any adverse event 460 (99) 270 (58) 46 (10) 219 (92) 80 (34) 6 (3) Diarrhea 251 (54) 45 (10) 1 (<1) 44 (19) 4 (2) 0 Decreased appetite 225 (48) 27 (6) 0 43 (18) 1 (<1) 0 Palmar–plantar erythrodysesthesia 217 (46) 79 (17) 0 12 (5) 0 0”